Cancer Therapeutics | Oncology Agents | Lymphomas & Myelomas
Resminostat in relapsed or refractory Hodgkin Lymphoma: Initial results of the SAPHIRE phase II trial with a novel oral histone deacetylase (HDAC) inhibitor
J Walewski*, E Pasziewicz-Kozik, G Borsaru, A Moicean, A Warszewska, K Strobel, A Biggi, B Hauns, A Mais, SW Henning, B Hentsch
*Corresponding author: J Walewski
Maria Sklodowska-Curie Memorial Institute and Oncology Center, Warszawa, Poland
F1000Posters 2010, 1: 705 (poster) [ENGLISH]
Poster [1.84 MB]
Presented at
52nd American Society of Hematology Annual Meeting 2010,
3 - 6 Dec 2010, 2811
The SAPHIRE study evaluates the therapeutic activity of the novel oral pan-HDAC inhibitor resminostat in relapsed/refractory Hodgkin Lymphoma (HL) patients after high dose chemotherapy and autologous hematopoietic stem cell transplantation. Resminostat is administered orally at a once daily dose of 600 mg in 2-week cycles consisting of 5 consecutive days treatment followed by a 9 day treatment free period. Patients undergo assessment of disease status by computed tomography in combination with positron emission tomography (PET/CT); PET/CT scans are conducted after cycle 3 and cycle 6 and thereafter every 4th cycle during an optional follow-up treatment period.
The trial is designed as an open-label, single-arm international trial with a Simon Minimax design and clinical data of the first recruitment phase (18 pts) on the efficacy and safety of resminostat are presented.
Consultancy for 4SC AG.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License
